IP Library Granted Patent US 10,583,178
Granted Patent B2
US 10,583,178 · App. 15/244,374 · Granted Mar 10, 2020

Compositions comprising sulforaphane or a sulforaphane precursor and a mushroom extract or powder

Inventors: Brian Cornblatt (Westminster, MD); Grace Cornblatt (Westminster, MD); Anton Bzhelyansky (Baltimore, MD); Robert Henderson (Street, MD)
Assignee: NUTRAMAX LABORATORIES, INC.
A61K38/47A23L33/105A61K9/0053A61K9/14A61K9/28A61K31/19A61K31/194A61K31/26A61K31/357A61K31/375A61K31/7028A61K31/716A61K33/06A61K36/06A61K36/07A61K36/28A61K36/31A61K45/06A61K47/42A61P3/06C12Y302/01147A23V2002/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,583,178
App. No.
15/244,374
Granted
Mar 10, 2020
Kind
B2
Abstract

The present disclosure relates to the synergistic combination of a sulforaphane precursor, an enzyme capable of converting the sulforaphane precursor to sulforaphane, a cofactor of the enzyme, and a glucan. The present disclosure also relates to the synergistic combination of sulforaphane or a derivative thereof and a glucan. The present disclosure also relates to the synergistic combination of a broccoli extract or powder and a glucan. The glucan may be a β-glucan. The glucan may be provided in a mushroom extract or powder selected from one or more of a maitake, a shiitake, or a reishi mushroom. Compositions and methods relating to these combinations are described.

Claims (31)

1. An orally administrable composition comprising a synergistic combination of:

a sulforaphane precursor;

a glucosidase enzyme capable of converting the sulforaphane precursor to sulforaphane;

a glucosidase enzyme cofactor; and

a glucan.

2. The orally administrable composition of claim 1 , wherein the sulforaphane precursor comprises glucoraphanin, the glucosidase enzyme comprises myrosinase, and the glucosidase enzyme cofactor comprises ascorbic acid.

3. The orally administrable composition of claim 1 , wherein the composition comprises an enteric-coated dosage form.

4. The orally administrable composition of claim 1 , wherein the composition comprises a mushroom extract or powder comprising the glucan.

5. The orally administrable composition of claim 1 , wherein the composition comprises a yeast extract or powder comprising the glucan.

6. The orally administrable composition of claim 1 , wherein the glucan is a β-glucan.

7. The orally administrable composition of claim 4 , wherein the mushroom extract or powder is derived from one or more of a maitake mushroom, a shiitake mushroom, and a reishi mushroom.

8. The orally administrable composition of claim 5 , wherein the yeast extract or powder is derived from a baker's yeast.

9. The orally administrable composition of claim 1 , wherein the composition further comprises one or more additional components selected from the group consisting of quercetin, an aminosugar, a glycosaminoglycan, avocado/soybean unsaponifiables, a vitamin, a coffee fruit, magnesium, silymarin, proanthocyanidins, ursolic acid, curcumin, phytosterols, and phytostanols.

10. The orally administrable composition of claim 1 , wherein the composition comprises glucoraphanin, myrosinase, ascorbic acid, and β-glucan.

11. The orally administrable composition of claim 10 , wherein the composition comprises glucoraphanin, myrosinase, ascorbic acid, and maitake mushroom extract or powder.

12. The orally administrable composition of claim 10 , wherein the composition comprises glucoraphanin, myrosinase, ascorbic acid, maitake mushroom extract or powder, and shiitake mushroom extract or powder.

13. The orally administrable composition of claim 1 , wherein the composition comprises a broccoli extract or powder comprising the sulforaphane precursor.

14. An orally administrable composition comprising a synergistic combination of:

a sulforaphane or sulforaphane derivative; and

a glucan.

15. The orally administrable composition of claim 14 , wherein the composition comprises an enteric-coated dosage form.

16. The orally administrable composition of claim 14 , wherein the composition comprises a mushroom extract or powder comprising the glucan.

17. The orally administrable composition of claim 14 , wherein the composition comprises a yeast extract or powder comprising the glucan.

18. The orally administrable composition of claim 14 , wherein the glucan is a β-glucan.

19. The orally administrable composition of claim 16 , wherein the mushroom extract or powder is derived from one or more of a maitake mushroom, a shiitake mushroom, and a reishi mushroom.

20. The orally administrable composition of claim 17 , wherein the yeast extract or powder is derived from a baker's yeast.

21. The orally administrable composition of claim 14 , wherein the composition further comprises one or more additional components selected from the group consisting of quercetin, an aminosugar, a glycosaminoglycan, avocado/soybean unsaponifiables, a vitamin, a coffee fruit, magnesium, silymarin, proanthocyanidins, ursolic acid, curcumin, phytosterols, and phytostanols.

22. The orally administrable composition of claim 14 , comprising sulforaphane or sulforaphane derivative and β-glucan.

23. The orally administrable composition of claim 16 , wherein the composition comprises sulforaphane or sulforaphane derivative and maitake mushroom extract or powder.

24. The orally administrable composition of claim 16 , wherein the composition comprises sulforaphane or sulforaphane derivative, maitake mushroom extract or powder, and shiitake mushroom extract or powder.

25. The orally administrable composition of claim 14 , wherein the composition comprises a broccoli extract or powder comprising the sulforaphane or sulforaphane derivative.

Continuity (11)
Continuation 14586765 · Dec 30, 2014
Continuation PCTUS2013049248 · Jul 3, 2013
Provisional Application 61668328 · Jul 5, 2012
Provisional Application 61668342 · Jul 5, 2012
Provisional Application 61668386 · Jul 5, 2012
Provisional Application 61668396 · Jul 5, 2012
Provisional Application 61668364 · Jul 5, 2012
Provisional Application 61668374 · Jul 5, 2012
Provisional Application 61794417 · Mar 15, 2013
Related Publication 20160354448A1 · Dec 8, 2016
Related Publication 20180200344A9 · Jul 19, 2018
Cited By (2)
US 12,558,384 US 12,648,979